Verve Therapeutics is a biotechnology company. The company's gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels.
Verve Therapeutics is focused on using CRISPR and gene editing techniques to treat coronary artery and cardiovascular disease.
Verve Therapeutics was founded in 2018 by Sekar Kathiresan, and other researchers in the area of cardiovascular genetics including Kiran Musunuru and J. Keith Joung. Verve's initial two programs target PCSK9 and ANGPTL3, two genes which have been validated by human genetics and pharmacology to be targets for lowering blood lipids. The company completed its initial public offering on the Nasdaq in June 2021, raising gross proceeds of $266.7 million.